Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?

• Үндсэн зохиолчид: Stephen T. Abedon (Зохиогч), Katarzyna M. Danis-Wlodarczyk (Зохиогч), Diana R. Alves (Зохиогч)
• Формат: Ном
• Хэвлэсэн: MDPI AG, 2021-11-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.
• Notes: 10.3390/ph14111157; 1424-8247
• Keywords: bacteriophage therapy; case study; clinical study; combination therapy; compassionate use; expanded access; Medicine; R; Pharmacy and materia medica; RS1-441
• Source: Pharmaceuticals, Vol 14, Iss 11, p 1157 (2021)

Many bacteriophages are obligate killers of bacteria. That this property could be medically useful was first recognized over one hundred years ago, with 2021 being the 100-year anniversary of the first clinical phage therapy publication. Here we consider modern use of phages in clinical settings. Our aim is to answer one question: do phages serve as effective anti-bacterial infection agents when used clinically? An important emphasis of our analyses is on whether phage therapy-associated anti-bacterial infection efficacy can be reasonably distinguished from that associated with often coadministered antibiotics. We find that about half of 70 human phage treatment reports-published in English thus far in the 2000s-are suggestive of phage-mediated anti-bacterial infection efficacy. Two of these are randomized, double-blinded, infection-treatment studies while 14 of those studies, in our opinion, provide superior evidence of a phage role in observed treatment successes. Roughly three-quarters of these potentially phage-mediated outcomes are based on microbiological as well as clinical results, with the rest based on clinical success. Since many of these phage treatments are of infections for which antibiotic therapy had not been successful, their collective effectiveness is suggestive of a valid utility in employing phages to treat otherwise difficult-to-cure bacterial infections.